dianova Anti-TIGIT (Hu) Clone TG1 is the first monoclonal antibody detecting #TIGIT in routine #FFPE tissue specimen by #IHC.

Validated for the identification of TIGIT positive #Tcells infiltrating human #tumours under pathological conditions.

www.stratech.co.uk/p...

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies

Interesting hypothesis about anti-TIGIT failure

“Selecting an unmutated IgG1 targeting TIGIT, LAG-3, TIM-3, or PD-1 may deplete effector T cells through CDC, ADCC, and/or ADCP, thereby counteracting anticancer efficacy”

#lcsm #tigit

🔬Dianova Anti-TIGIT (Hu) Clone TG1 is the first monoclonal #antibody detecting #TIGIT in routine #FFPE tissue specimen by #IHC

Validated for the identification of TIGIT positive #Tcells infiltrating human #tumours under pathological conditions

🔗www.stratech.co.uk/p...

dianova Anti-TIGIT (Hu) Clone TG1 is the first monoclonal antibody detecting #TIGIT in routine #FFPE tissue specimen by #IHC. Validated for the identification of TIGIT positive #Tcells infiltrating human #tumours under pathological conditions.

www.stratech.co.uk/products/DIA...

#diagnostics

Inhibitory receptor TIGIT
mabnusbiotech.substack.com/p/inhibitory...
#TIGIT #Lifescience #Biology #Mabnus

BIOZOL GmbH Dianova Clone TG1 is the first monoclonal #antibody for #IHC detection of #cancer #immunology checkpoint biomarker #TIGIT (Tcell immunoreceptor with Ig & ITIM domains) in standard #FFPE human tissue specimen
https://www.stratech.co.uk/products/DIA-TG1-M-DIA/

#diagnostics #histopathology

BIOZOL GmbH Dianova Clone TG1 is the first monoclonal #antibody for #IHC detection of #cancer #immunology checkpoint biomarker #TIGIT (Tcell immunoreceptor with Ig & ITIM domains) in standard #FFPE human tissue specimen

www.stratech.co.uk/p...

#diagnostics #histopathology

#dianova Anti-TIGIT (Hu) Clone TG1 is the first monoclonal antibody detecting #TIGIT in routine #FFPE tissue specimen by #IHC Validated for the identification of TIGIT positive #Tcells infiltrating human #tumours under pathological conditions

More here: stratech.co.uk/produ...

.#dianova Anti-TIGIT (Hu) Clone TG1 is the first monoclonal antibody detecting #TIGIT in routine #FFPE tissue specimen by #IHC

Validated for the identification of TIGIT positive #Tcells infiltrating human #tumours under pathological conditions

More here: www.stratech.co.uk/products/DIA...

Emerging roles of checkpoint molecules on B cells Immune checkpoint molecules, including both co-inhibitory molecules and co-stimulatory molecules, are known to play critical roles in regulating T-cell responses. During the last decades, immunothe...

www.tandfonline.com/doi/full/10....
Emerging roles of checkpoint molecules on B cells
#Bcells #TIM-1 #TIGIT #PD-1

Exploring TIGIT Dimers: A New Frontier in Cancer Immunotherapy

What’s unique about #TIGIT? Unlike other immune checkpoints, TIGIT modulates both T and NK cells, presenting new opportunities to tackle resistant #cancers, especially when paired with PD-1 inhibitors. bit.ly/40zDp2P

Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab - Merck.com Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezeli...

Development of two next gen IO molecules has been discontinued. Vibostolimab (anti #TIGIT) and favezelimab (anti LAG3) programs both being shuttered. Development in this space has been significantly hampered by the lack of predictive biomarkers.

www.merck.com/news/merck-p...

2) 💥Wow! Prof. Elizabeth M Burton #immunotherapy expert @mdanderson.bsky.social shows that high #B7H3 ( #PDL3 / #CD276 ) correlates with non-responders to neoadjuvant IO/ High #TIGIT & Low #B7H3 was assoc with responders/marker of T cell activation? #Bridge2024 @sitcancer.bosky.social

Still amazes me how positivity for #TIGIT ligands expression is not added as inclusion criteria in these trials, as done for PD-L1. Any rationale for not including it?

#biosky #oncology

Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III SKYSCRAPER-01 study, evaluating tiragolumab co

SKYSCRAPER-01 has failed in overall survival

Long awaited results from Genentech/Roche on SKYSCRAPER-01, a Phase 3 evaluating the anti #TIGIT tiragolumab in combo with Tecentriq vs Tecentriq alone for patients w PD-L1-high, locally advanced or metastatic NSCLC

www.businesswire.com/news/home/20...

It's true that the #TIGIT space has seen ups and downs in the last few years. Curious to see clinical trials implementing better patient stratification strategies based on epithelial/mesenchymal markers to improve responses to #immunotherapy!

Interesting summary of #morpheusliver #HCC data and issues. #tigit inh. #tiragolumab + #tecentriq #avastin performed well vs. #IMBRAVE150 doublet but latter underperformed. PFS unprecedented. Exciting but await #IMBRAVE152 to confirm #livertwitter...